A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia-Reference-Cited by-同舟云学术

A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia

Published:2010-12 Issue:12 Volume:34 Page:1622-1626
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Advani Anjali S.,Tiu Ramon,Saunthararajah Yogen,Maciejewski Jaroslaw,Copelan Edward A.,Sobecks Ronald,Sekeres Mikkael A.,Bates Jennifer,Rush Mary Lynn,Tripp Barbara,Salvado August,Noon Elysa,Howard Matthew,Jin Tao,Hsi Eric,Egorin Merrill J.,Lim Kathleen,Cotta Claudiu V.,Price Courtney,Kalaycio Matt

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference20 articles.

1. The search for optimal treatment in relapsed and refractory acute myeloid leukemia;Robak;Leukemia & Lymphoma,2002

2. Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia;Hans;American Journal of Clinical Pathology,2002

3. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, kitI/c-kit signaling the other;Domen;Journal of Experimental Medicine,2000

4. Amount of spontaneous apoptosis detected by bax/bcl-2 ratio predicts outcome in acute myeloid leukemia (AML);Del Poeta;Blood,2003

5. Early signaling pathways activated by c-kit in hematopoietic progenitor cells;Linnekin;International Journal of Biochemistry and Cell Biology,1999

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia;Biomedicines;2024-08-06

2. Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target;Aspects of Molecular Medicine;2023-12

3. A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression;American Journal of Hematology;2023-01-22

4. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia;International Journal of Molecular Sciences;2022-04-23

5. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy;Signal Transduction and Targeted Therapy;2020-12